GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum
This article was originally published in The Pink Sheet Daily
Executive Summary
Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.
You may also be interested in...
Spectrum Licenses Third-Generation Taxane From Italian Firm Indena
The new chemical entity has demonstrated activity in taxane-refractory tumors, Spectrum said.
Spectrum Licenses Third-Generation Taxane From Italian Firm Indena
The new chemical entity has demonstrated activity in taxane-refractory tumors, Spectrum said.
GPC Completes Satraplatin Rolling NDA
Company is requesting priority review for use of the novel oral platinum drug in second-line hormone refractory prostate cancer.